株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

潰瘍性大腸炎 (UC) - 世界の医薬品の予測と市場分析

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

発行 GlobalData 商品コード 299707
出版日 ページ情報 英文 345 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.31円で換算しております。
Back to Top
潰瘍性大腸炎 (UC) - 世界の医薬品の予測と市場分析 PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025
出版日: 2017年01月13日 ページ情報: 英文 345 Pages
概要

世界の主要7ヶ国 - 米国、フランス、ドイツ、イタリア、スペイン、英国、日本 - における潰瘍性大腸炎 (UC) 治療薬の市場規模は、2015年には56億4000万米ドル、2025年には65億8000万米ドルと、1.6%のCAGR (複合年間成長率) で拡大する見通しです。特に、9種類ものパイプライン製品や、抗TNFα製剤のバイオシミラーなどが上市される予定で、それが今後の市場成長の主な要因となっています。

当レポートでは、全世界の潰瘍性大腸炎 (UC) の市場の現状と将来展望について分析し、疾患の概要や今後の疫学的予測、主要国での予防体性、主要企業のプロファイルと代表的製品、市場のアンメットニーズと将来的な機会、現在治験中のパイプライン製品の情報、今後の市場規模と影響要因などを調査しております。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態
  • 分類と病期
  • 症状
  • 生活の質 (QoL)

第4章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界的傾向
    • 発症件数
    • 有病者数
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
    • 利用しなかった情報源
  • 潰瘍性大腸炎 (UC) の疫学的予測 (通算11年間分)
    • UCの診断済みの発症件数
    • UCの診断済みの有病者数
    • UCの未受診の有病者数
    • 有病者総数
    • 未決定性大腸炎 (IC) の診断済みの発症件数
    • ICの診断済みの有病者数
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 診断・治療の概要
    • 診断
    • 治療のガイドラインと代表的な処方薬
    • 臨床診療
  • 米国
  • 欧州主要5ヶ国 (5EU)
  • 日本

第6章 市場競争の分析

  • 概要
  • 製品プロファイル:潰瘍性大腸炎 (UC)
    • 5-アミノサリチル酸 (5-ASA)
    • ステロイド
    • チオプリン
    • その他の免疫調整剤
    • 抗TNFα製剤 (Remicade、Humira、Simponi)
    • 抗インテグリン抗体 (Entyvio)
    • バイオシミラー

第7章 アンメットニーズと市場機会

  • 概要
  • 抗TNFα製剤による治療の不十分さ
    • アンメットニーズ
    • ギャップ分析
    • 市場機会
  • 患者アドヒアランス
  • 安全・効果的・低価格の代替的治療薬の欠如
  • 新たな経口治療薬のニーズ
  • 関連疾患 (大腸癌) リスクの引き下げのための予防薬

第8章 パイプライン評価

  • 概要
  • 治験段階にある有望な医薬品
    • ウステキヌマブ (Stelara、Suterara、CNTO-1275)
    • エトロリズマブ
    • LT-02 (ホスファチジルコリン)
    • Kappaproct
    • Xeljanz (トファシチニブ、Cp-690,550)
    • オザニモド塩酸塩
    • カロテグラスト (AJM300)
    • メサラミン (TP-05)
    • AJG511
  • バイオシミラー
    • 概要
    • インフリキシマブのバイオシミラー
    • アダリムマブのバイオシミラー
    • 予測

第9章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • Johnson & Johnson (J&J)
    • AbbVie
    • 武田薬品工業
    • Salix Pharmaceuticals
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • InDex Pharmaceuticals
    • Lipid Therapeutics GmbH
    • Celgene Corporation
    • EA Pharma
    • Ferring International
    • Tillotts Pharma

第10章 市場の将来展望

  • 世界市場
    • 市場予測
    • 促進・阻害要因:世界的課題
  • 米国
    • 市場予測
    • 近年の主な動向
    • 市場促進・阻害要因
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本

第11章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of the colon and rectum. As a result, the colon's ability to absorb water is decreased, which leads to progressive loosening of the stool, bloody stool, and sometimes cramping or abdominal pain, with urgency for bowel movement. Other associated symptoms of UC include loss of appetite, weight loss, fatigue, and anaemia in cases of severe bleeding.

It is estimated that the 2015 Ulcerative Colitis (UC) drug sales to be $5.64B across the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in this report. By the end of the forecast period in 2025, sales will increase to over $6.58B at a Compound Annual Growth Rate (CAGR) of 1.6%, which is driven by approval/launch of nine pipeline therapies and anti-tumor necrosis factor (TNF) biosimilars.

In general, companies that are striving to enter the UC market are targeting all mild, moderate and severe UC patients. However, majority of late pipeline products are targeting UC patients refractory to steroids and anti-TNF therapies as well as anti-TNF naive patients, as this population remains the most underserved group, with limited therapeutic options and high clinical unmet need.

Johnson & Johnson's (J&J's) Remicade was market leader in 2015 with $1.4B in sales for UC. However, the brand will be experiencing significant erosion from biosimilars across 7MM throughout the 10 year forecast period. To mitigate brand erosion in France, J&J has reduced Remicade price in the country and is available at a same price as its biosimilars, leaving the market more competitive.

The report "PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025" provides an overview of UC, including epidemiology, aetiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In particular, it provides the following -

  • Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Provides strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics market.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned this report: Johnson & Johnson, AbbVie, Takeda Pharmaceuticals, Salix Pharmaceuticals, Pfizer, Roche, InDeX Pharmaceuticals, Lipid Therapeutics, Celgene, EA Pharma, Ferring, Tillotts Pharma

Scope

  • Overview of UC, including epidemiology, aetiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global UC therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification or Staging Systems
  • 3.3. Symptoms
  • 3.4. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. Incidence
    • 4.3.2. Prevalence
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for UC (2015-2025)
    • 4.5.1. Diagnosed Incident Cases of UC
    • 4.5.2. Diagnosed Prevalent Cases of UC
    • 4.5.3. Undiagnosed Prevalent Cases of UC
    • 4.5.4. Total Prevalent Cases of UC
    • 4.5.5. Diagnosed Incident Cases of IC
    • 4.5.6. Diagnosed Prevalent Cases of IC
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis
    • 4.6.4. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. 5EU
  • 5.4. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Ulcerative Colitis
    • 6.2.1. 5-ASAs
    • 6.2.2. Steroids
    • 6.2.3. Thiopurines
    • 6.2.4. Other Immunomodulators
    • 6.2.5. Anti-TNFα drugs (Remicade, Humira, Simponi)
    • 6.2.6. Anti-integrins (Entyvio)
    • 6.2.7. Biosimilars

7. Unmet Needs Assessment and Opportunity Analysis

  • 7.1. Overview
  • 7.2. Inadequacy of current anti-TNF- α drug treatment
    • 7.2.1. Unmet need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Patient Adherence
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Lack of safe, efficacious and less costly treatment alternatives
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Need for novel oral therapies
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Preventative Medicine for Lowering the Associated Colorectal Cancer Risk
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Ustekinumab (Stelara, Suterara, CNTO-1275)
    • 8.2.2. Etrolizumab
    • 8.2.3. LT-02(phosphatidylcholine)
    • 8.2.4. Kappaproct
    • 8.2.5. Xeljanz (Tofacitinib, Cp-690,550)
    • 8.2.6. Ozanimod hydrochloride
    • 8.2.7. Carotegrast (AJM300)
    • 8.2.8. Mesalamine (TP-05)
    • 8.2.9. AJG511
  • 8.3. Biosimilars
    • 8.3.1. Overview
    • 8.3.2. Infliximab biosimilars
    • 8.3.3. Adalimumab biosimilars
    • 8.3.4. Forecast

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Johnson & Johnson (J&J)
    • 9.3.2. AbbVie
    • 9.3.3. Takeda Pharmaceuticals
    • 9.3.4. Salix Pharmaceuticals
    • 9.3.5. Pfizer Inc.
    • 9.3.6. F. Hoffmann-La Roche Ltd.
    • 9.3.7. InDex Pharmaceuticals
    • 9.3.8. Lipid Therapeutics GmbH
    • 9.3.9. Celgene Corporation
    • 9.3.10. EA Pharma
    • 9.3.11. Ferring International
    • 9.3.12. Tillotts Pharma

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Prevalent Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Analyst
    • 11.7.3. Reviewer
    • 11.7.4. Therapy Area Director
    • 11.7.5. Epidemiologist
    • 11.7.6. Managing Epidemiologist
    • 11.7.7. Global Director of Therapy Analysis and Epidemiology
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Genetic factors implicated in UC causation
  • Table 2: Truelove and Witts categorization of disease severity and clinical parameters
  • Table 3: Pediatric Ulcerative Colitis Activity Index
  • Table 4: Typical Symptoms of UC
  • Table 5: Risk Factors and Comorbidities for UC and IBD
  • Table 6: Incidence of UC in the 5EU
  • Table 7: Prevalence of UC in Italy, Spain, and the UK
  • Table 8: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of UC
  • Table 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of UC
  • Table 10: 7MM, Sources Used to Forecast Undiagnosed Prevalent Cases of UC
  • Table 11: 7MM, Sources Used to Forecast the Total Prevalent Cases of UC
  • Table 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of UC by Stage at Diagnosis
  • Table 13: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Incident/Prevalent Cases of UC by Severity
  • Table 14: 7MM, Sources of Epidemiological Data used to Forecast Mortality Due to CRC and TMC Among the Diagnosed Prevalent Cases of UC
  • Table 15: 7MM, Sources Used to Forecast Autoimmune Comorbidities Among the Diagnosed Prevalent Cases of UC
  • Table 16: 7MM, Sources Used to Forecast UC Cases Requiring Colectomy Among the Diagnosed Prevalent Cases of UC Due to Failure of Medical Management
  • Table 17: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of IC
  • Table 18: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IC
  • Table 19: 7MM, Sources Not Used in Epidemiological Analysis of UC
  • Table 20: 7MM, Diagnosed Incident Cases of UC, Both Sexes, All Ages, N, Selected Years 2015-2025
  • Table 21: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, N (Row %), 2015
  • Table 22: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N (Row %), 2015
  • Table 23: 7MM, Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, Selected Years, 2015-2025
  • Table 24: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N (Row %), 2015
  • Table 25: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N (Row %), 2015
  • Table 26: 7MM, Undiagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, Select Years, 2015-2025
  • Table 27: 7MM, Age-Specific Undiagnosed Prevalent Cases of UC, Both Sexes, N (Row %), 2015
  • Table 28: 7MM, Sex-Specific Undiagnosed Prevalent Cases of UC, All Ages, N (Row %), 2015
  • Table 29: 7MM, Total Prevalent Cases of UC, Both Sexes, All Ages, N, Selected Years, 2015-2025
  • Table 30: 7MM, Age-Specific Total Prevalent Cases of UC, Both Sexes, N (Row %), 2015
  • Table 31: 7MM, Sex-Specific Total Prevalent Cases of UC, All Ages, N (Row %), 2015
  • Table 32: 7MM, Diagnosed Incident Cases of IC, Both Sexes, All Ages, N, Selected Years, 2015-2025
  • Table 33: 7MM, Diagnosed Prevalent Cases of IC, Both Sexes, All Ages, N, Selected Years, 2015-2025
  • Table 34: Diagnostic features of UC
  • Table 35: Truelove and Witts categorization of disease severity and clinical parameters
  • Table 36: UCDAI
  • Table 37: Pediatric Ulcerative Colitis Activity Index
  • Table 38: Treatment Guidelines for Ulcerative Colitis
  • Table 39: Most Prescribed Drugs for Ulcerative Colitis by Class in the Global Markets, 2015
  • Table 40: Different 5-ASAs used for managing UC
  • Table 41: Different corticosteroids used for managing UC
  • Table 42: Country Profile - US
  • Table 43: Region Profile - 5EU
  • Table 44: Country Profile - Japan
  • Table 45: Leading Treatments for UC, 2015
  • Table 46: Product Profile - Lialda
  • Table 47: Efficacy of different drugs in 5-ASA class in inducing remission in UC patients
  • Table 48: Efficacy of different drugs in 5-ASA class in preventing disease relapse in UC patients
  • Table 49: Percentage of patients experiencing adverse events with 5-ASAs
  • Table 50: 5-ASA SWOT Analysis, 2015
  • Table 51: Product Profile -Steroids
  • Table 52: Efficacy of Uceris
  • Table 53: Safety of Uceris
  • Table 54: Uceris SWOT Analysis, 2016
  • Table 55: Product Profile -Azathioprine
  • Table 56: Percentage of patients experiencing adverse events with AZA and 6-MP therapy
  • Table 57: Azathioprine SWOT Analysis, 2015
  • Table 58: Product Profile -MTX
  • Table 59: MTX SWOT Analysis, 2015
  • Table 60: Product Profile -Remicade
  • Table 61: Efficacy data for ACT 1 and ACT 2 trials
  • Table 62: Safety of Remicade
  • Table 63: SWOT Analysis, Remicade 2016
  • Table 64: Product Profile -Humira
  • Table 65: Efficacy of Humira - Primary and Secondary Endpoints-ULTRA 2 Phase III Program
  • Table 66: SWOT Analysis, Humira 2016
  • Table 67: Product Profile -Simponi
  • Table 68: Efficacy of Simponi
  • Table 69: Safety of Simponi
  • Table 70: Simponi SWOT Analysis, 2016
  • Table 71: Product Profile - Entyvio
  • Table 72: Efficacy of Entyvio
  • Table 73: Efficacy of Entyvio
  • Table 74: Safety of Entyvio
  • Table 75: Entyvio SWOT Analysis
  • Table 76: Infliximab Biosimilars for UC Treatment
  • Table 77: Product Profile -Infliximab biosimilar
  • Table 78: Percentage of patients experiencing adverse events with infliximab biosimilars
  • Table 79: Biosimilars SWOT Analysis, 2015
  • Table 80: Unmet Need and Opportunity in UC, 2015
  • Table 81: Late stage development drugs for UC, 2015-2025
  • Table 82: Product Profile - Ustekinumab
  • Table 83: Ustekinumab SWOT Analysis, 2015
  • Table 84: Product Profile - Etrolizumab
  • Table 85: Efficacy of Etrolizumab
  • Table 86:Safety of Etrolizumab
  • Table 87 : Pipeline Drug Etrolizumab SWOT Analysis, 2016
  • Table 88: Product Profile - LT-02
  • Table 89: Efficacy Analysis for LT-02
  • Table 90: Efficacy Analysis for Different Doses of LT-02
  • Table 91: LT-02 SWOT Analysis, 2015
  • Table 92: Product Profile - Kappaproct
  • Table 93: Safety of Kappaproct
  • Table 94: Kappaproct SWOT Analysis, 2016
  • Table 95: Product Profile - Xeljanz
  • Table 96: Patient reported outcomes for Xeljanz compared to placebo
  • Table 97: Mean change from baseline in partial Mayo score in Xeljanz and placebo groups
  • Table 98: Mean change from baseline in partial Mayo score in Xeljanz and placebo groups
  • Table 99: Rates of various adverse events experienced in Xeljanz and placebo groups
  • Table 100: Xeljanz SWOT Analysis, 2015
  • Table 101: Product Profile - Ozanimod hydrochloride
  • Table 102: Efficacy analysis of Ozanimod
  • Table 103: Safety of Ozanimod
  • Table 104: Pipeline Drug Ozanimod SWOT Analysis, 2015
  • Table 105: Product Profile - Carotegrast
  • Table 106: Efficacy analysis in carotegrast and placebo groups
  • Table 107: Safety analysis of carotegrast
  • Table 108: Carotegrast SWOT Analysis, 2015
  • Table 109: Product Profile - Mesalamine (TP-05)
  • Table 110: Pipeline Drug TP-05 SWOT Analysis, 2016
  • Table 111: Product Profile - AJG511
  • Table 112: Efficacy analysis of AJG511
  • Table 113: Carotegrast SWOT Analysis, 2015
  • Table 114: Product Profile - Infliximab biosimilars
  • Table 115: Infliximab biosimilars SWOT Analysis, 2015
  • Table 116: Product Profile - Amjevita
  • Table 117: Amjevita SWOT Analysis, 2016
  • Table 118: Key Companies in the Ulcerative Colitis Market in the 7MM, 2015
  • Table 119: J&J's UC Portfolio Assessment, 2015
  • Table 120: AbbVie's UC Portfolio Assessment, 2015
  • Table 121: Takeda's UC Portfolio Assessment, 2015
  • Table 122: Salix Pharmaceuticals' UC Portfolio Assessment, 2015
  • Table 123: Pfizer's UC Portfolio Assessment, 2015
  • Table 124: Roches UC Portfolio Assessment, 2015
  • Table 125: InDex Pharmaceutical's UC Portfolio Assessment, 2015
  • Table 126: Lipid Therapeutics' UC Portfolio Assessment, 2015
  • Table 127: Celgene's UC Portfolio Assessment, 2015
  • Table 128: EA Pharma's UC Portfolio Assessment, 2015
  • Table 129: Ferring Pharmaceuticals' UC Portfolio Assessment, 2015
  • Table 130: Tillotts Pharma's UC Portfolio Assessment, 2015
  • Table 131:Ulcerative Colitis Market - Global Drivers and Barriers, 2015?2025
  • Table 132: Key Events Impacting Sales for Ulcerative Colitis in the US, 2015-2025
  • Table 133: Ulcerative Colitis Market - Drivers and Barriers in the US, 2015?2025
  • Table 134: Key Events Impacting Sales for Ulcerative Colitis in France, 2015-2025
  • Table 135: Ulcerative Colitis Market - Drivers and Barriers in France, 2015?2025
  • Table 136: Key Events Impacting Sales for Ulcerative Colitis in Germany, 2015-2025
  • Table 137: Ulcerative Colitis Market - Drivers and Barriers in Germany, 2015?2025
  • Table 138: Key Events Impacting Sales for Ulcerative Colitis in Italy, 2015-2025
  • Table 139: Ulcerative Colitis Market - Drivers and Barriers in Italy, 2015?2025
  • Table 140: Key Events Impacting Sales for Ulcerative Colitis in Spain, 2015-2025
  • Table 141: Ulcerative Colitis Market - Drivers and Barriers in Spain, 2015?2025
  • Table 142: Key Events Impacting Sales for Ulcerative Colitis in the UK, 2015-2025
  • Table 143: Ulcerative Colitis Market - Drivers and Barriers in UK, 2015?2025
  • Table 144: Key Events Impacting Sales for Ulcerative Colitis in Japan, 2015-2025
  • Table 145: Ulcerative Colitis Market - Drivers and Barriers in Japan, 2015?2025
  • Table 146: Key Projected Launch Dates for UC
  • Table 147: Key Historical and Projected Patent Expiry Dates for UC
  • Table 148: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: 7MM, Diagnosed Incident Cases of UC, Both Sexes, All Ages, Selected Years, 2015-2025
  • Figure 3: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, All Ages, N, 2015
  • Figure 4: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N, 2015
  • Figure 5: 7MM, Age-Standardized Diagnosed Incidence of UC (Cases per 100,000 Population), All Ages, Both Sexes, N, 2015
  • Figure 6: 7MM, Diagnosed Incident Cases of UC Segmented by Stage at Diagnosis, Both Sexes, All Ages, N, 2015
  • Figure 7: 7MM, Diagnosed Incident Cases of UC Segmented by Severity, Both Sexes, All ages, N, 2015
  • Figure 8: 7MM, Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, Selected Years, 2015-2025
  • Figure 9: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N, 2015
  • Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N, 2015
  • Figure 11:7MM, Age-Standardized Diagnosed Prevalence of UC, All Ages, Both Sexes, %, 2015
  • Figure 12: 7MM, Diagnosed Prevalent Cases of UC Segmented by Severity, Both Cases, All Ages, N, 2015
  • Figure 13: 7MM, Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2015
  • Figure 14: 7MM, Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2015
  • Figure 15: 7MM. Comorbidities Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2015
  • Figure 16: 7MM, Undiagnosed Prevalent Cases of UC, Both Sexes, All Ages, Selected Years, N, 2015-2025
  • Figure 17: 7MM, Age-Specific Undiagnosed Prevalent Cases of UC, Both Sexes, N, 2015
  • Figure 18: 7MM, Sex-Specific Undiagnosed Prevalent Cases of UC, All Ages, N, 2015
  • Figure 19: 7MM, Age-Standardized Undiagnosed Prevalence of UC, All Ages, Both Sexes, %, 2015
  • Figure 20: 7MM, Total Prevalent Cases of UC, Both Sexes, All Ages, Selected Years, N, 2015-2025
  • Figure 21: 7MM, Age-Specific Total Prevalent Cases of UC, Both Sexes, N, 2015
  • Figure 22: 7MM, Sex-Specific Total Prevalent Cases of UC, All Ages, N, 2015
  • Figure 23: 7MM, Age-Standardized Total Prevalence of UC, All Ages, Both Sexes, %, 2015
  • Figure 24: 7MM, Diagnosed Incident Cases of IC, Both Sexes, All Ages, Selected Years, N, 2015-2025
  • Figure 25: 7MM, Diagnosed Prevalent Cases of IC, Both Sexes, All Ages, Selected Years, N, 2015-2025
  • Figure 26 : Ulcerative Colitis Treatment Algorithm
  • Figure 27: Global Sales for Ulcerative Colitis by Drug Class, 2015 and 2025
  • Figure 28: Sales for Ulcerative Colitis by Drug Class in the US, 2015 and 2025
  • Figure 29: Sales for Ulcerative Colitis by Drug Class in France, 2015 and 2025
  • Figure 30: Sales for Ulcerative Colitis by Drug Class in Germany, 2015 and 2025
  • Figure 31: Sales for Ulcerative Colitis by Drug Class in Italy, 2015 and 2025
  • Figure 32: Sales for Ulcerative Colitis by Drug Class in Spain, 2015 and 2025
  • Figure 33: Sales for Ulcerative Colitis by Drug Class in the UK, 2015 and 2025
  • Figure 34: Sales for Ulcerative Colitis by Drug Class in Japan, 2015 and 2025
Back to Top